Pharmaceutical

Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy

Chinese NMPA approves Innovent and IASO Bio’s myeloma t...

Jul 3, 2023

China has granted approval for Innovent Biologics and IASO Bio Fucaso for treati...

Madrigal seeks expedited approval for NASH treatment

Madrigal seeks expedited approval for NASH treatment

Jul 3, 2023

Madrigal Pharmaceuticals has commenced a rolling submission of an NDA seeking ex...

STAT+: Medical leaders decry Supreme Court decision on affirmative action

STAT+: Medical leaders decry Supreme Court decision on ...

Jul 2, 2023

Medical leaders reacted swiftly to the Supreme Court’s decision on affirmative a...

STAT+: Supreme Court strikes down use of affirmative action, a blow to efforts to diversify medical schools

STAT+: Supreme Court strikes down use of affirmative ac...

Jul 2, 2023

The U.S. Supreme Court struck down the use of affirmative action, ruling that it...

Eculizumab biosimilar by Turgut Ilaclari for Neuromyeli...

Jul 1, 2023

Eculizumab biosimilaris under clinical development by Turgut Ilaclari and curren...

(Glucagon + insulin human) by Abvance Therapeutics for ...

Jul 1, 2023

(Glucagon + insulin human)is under clinical development by Abvance Therapeutics ...

KP-910 by Kaken Pharmaceutical for Peripheral Neuropath...

Jul 1, 2023

KP-910is under clinical development by Kaken Pharmaceutical and currently in Pha...

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Me...

Jul 1, 2023

[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics an...

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry ...

Jul 1, 2023

ABBV-444is under clinical development by AbbVie and currently in Phase III for K...

XKDCT-080 by Guangdong Xiankangda Biotechnology for Col...

Jul 1, 2023

XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and...

Immune Thrombocytopenia by NovelMed Therapeutics for Id...

Jul 1, 2023

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics an...

Cold agglutinin disease by NovelMed Therapeutics for Ac...

Jul 1, 2023

Cold agglutinin diseaseis under clinical development by NovelMed Therapeutics an...

SNK-396 by Synerk for Lipid Disorders: Likelihood of Ap...

Jul 1, 2023

SNK-396is under clinical development by Synerk and currently in Phase I for Lipi...

IN-14199 by HK inno.N for Constipation: Likelihood of A...

Jul 1, 2023

IN-14199is under clinical development by HK inno.N and currently in Phase I for ...

We have a cure for hepatitis C — so why aren’t more people getting treatment?

We have a cure for hepatitis C — so why aren’t more peo...

Jun 30, 2023

New data shows that among adults under the age of 40, only 1 in 4 people with he...

STAT+: Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa

STAT+: Alkermes shareholders re-elect directors, rebuff...

Jun 30, 2023

Alkermes shareholders voted to re-elect all of the drugmaker’s current directors...